This episode of The Motley Fool's Market Checkup dives into the hottest headlines, looks at the biggest market movers in the health-care sector, and discusses the implementation of the Affordable Care Act, also known as Obamacare.
In this segment, analysts David Williamson and Max Macaluso discuss the reasons behind today's 40% drop in shares of Ariad Pharmaceuticals (NASDAQ: ARIA ) , an oncology-focused biotech company that is facing major headwinds regarding its chronic myeloid leukemia drug Iclusig.
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.